These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1665490)

  • 1. A randomised study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer.
    Anderson H; Prendiville J; Thatcher N; Radford JA; Swindell R
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S139-40. PubMed ID: 1665490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.
    Anderson H; Hopwood P; Prendiville J; Radford JA; Thatcher N; Ashcroft L
    Br J Cancer; 1993 Jun; 67(6):1385-90. PubMed ID: 8390287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
    Skubitz KM; Hamdan H; Thompson RC
    Cancer; 1993 Nov; 72(10):2963-9. PubMed ID: 8221562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
    Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
    Cantwell BM; Bozzino JM; Corris P; Harris AL
    Eur J Cancer Clin Oncol; 1988 Feb; 24(2):123-9. PubMed ID: 2833398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC; Ettinger DS; Neuberg D; Comis RL; Ruckdeschel JC; Bonomi PD; Johnson DH
    J Clin Oncol; 1995 Jul; 13(7):1615-22. PubMed ID: 7602350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.
    Kamthan AG; Lind MJ; Thatcher N; Steward WP; Bronchud MH; Ranson MR; Stout R
    Eur J Cancer; 1990; 26(6):691-4. PubMed ID: 2168191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
    Bleehen NM; Girling DJ; Machin D; Stephens RJ
    Br J Cancer; 1993 Dec; 68(6):1157-66. PubMed ID: 7505104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy for poor-risk patients with small-cell lung cancer using bolus ifosfamide and oral etoposide.
    Anderson H; Lind MJ; Thatcher N; Swindell R; Woodcock A; Carroll KB
    Cancer Chemother Pharmacol; 1990; 26(1):71-4. PubMed ID: 2157555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer.
    Chen YM; Wu MF; Perng RP; Chou CM; Yang KY; Lin WC; Tsai CM; Liu JM; Whang-Peng J
    Jpn J Clin Oncol; 1997 Apr; 27(2):76-9. PubMed ID: 9152794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
    Shirinian M; Lee JS; Dhingra HH; Greenberg J; Hong WK
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):49-53. PubMed ID: 1329212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working Party.
    Sculier JP; Bureau G; Giner V; Thiriaux J; Michel J; Berchier MC; Van Cutsem O; Küstner U; Kroll F; Mommen P
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):18-22. PubMed ID: 7846537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ifosfamide and adriamycin after induction with cisplatin and etoposide (VP-16) in pulmonary microcytoma. Preliminary results].
    Antilli A; Cruciani AR; Nunziati F; Orazi D; Portalone L; Signora M; Salvati F
    G Ital Chemioter; 1985; 32(1):71-2. PubMed ID: 3007254
    [No Abstract]   [Full Text] [Related]  

  • 19. Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
    Huang YJ; He AN; Sun YJ; Shen Z; Min DL; Yao Y
    Asian Pac J Cancer Prev; 2015; 16(6):2391-5. PubMed ID: 25824770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer.
    Drings P; Abel U; Bülzebruck H; Stiefel P; Kleckow M; Manke HG
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S34-9. PubMed ID: 3028662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.